Home > Insider Trading > Filing (0001600620-25-000022)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1600620	Aurinia Pharmaceuticals Inc.	AUPH	Pharmaceutical Preparations (2834)	981231763

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
2044006	Greg Keenan	#140, 14315 - 118 Avenue Edmonton A0 T5L 4S6	Chief Medical Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2025-02-28	62,583	$0.00	174,028	No	4	A	Direct
Common Stock	Disposition	2025-03-03	12,239	$8.00	161,789	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	A	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Employee Stock Option (right to buy)	Acquisiton	2025-02-28	95,570	$0.00	95,570	$7.55

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
95,570		2035-02-28	No	4	A	Direct

Footnotes

Each performance right represents a contingent right to receive one common share of the Issuer. The performance rights vest in four tranches upon the Issuer's common shares achieving fourprogressively higher target prices, with respective one year retention periods per tranche achievement.
Represents the number of shares automatically sold to cover tax withholding obligations in connection with the vesting of Restricted Stock Units related to the January 30, 2024 grant.
The price in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.79 to $8.13, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
One-third of the shares subject to the option vests twelve months from the grant date, and the remainder vests in twenty-four equal monthly installments thereafter.